Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To analyze the relationship between the dynamic changes of circulating tumor DNA (ctDNA) and tumor relapse of esophageal squamous cell carcinoma treated by concurrent chemoradiotherapy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ctDNA(+) Cohort | ctDNA(+) Cohort in pretreatment and posttreatment plasma samples was defined by accessing the presence of one or more mutations identified in match tumor samples. | ||
| ctDNA(-) Cohort | ctDNA(-) Cohort in pretreatment and posttreatment plasma samples was defined by the absence of one or more mutations identified in match tumor samples. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Relationship between ctDNA status after chemoradiotherapy and relapse. | To assess if recurrent esophageal cancer is detectable earlier by ctDNA positive in plasma. | ctDNA will be tested within 1 year after chemoradiotherapy |
| Measure | Description | Time Frame |
|---|---|---|
| Changes of ctDNA status. | To dynamically evaluate the ctDNA status at baseline, during treatment and follow-up. | before and at the end of radiotherapy (+1 week); at the end of consolidation chemotherapy (+1 week); at 2 weeks, 1 month, 3 months, 6 months, 9 months, 1 year after dCCRT. |
| Overall survival (OS). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Local advanced esophageal squamous cell carcinoma treated by definitive concurrent chemoradiotherapy
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fudan University Shanghai cancer center | Recruiting | Shanghai | Shanghai Municipality | 200032 | China |
Not provided
| ID | Term |
|---|---|
| D000077277 | Esophageal Squamous Cell Carcinoma |
| ID | Term |
|---|---|
| D002294 | Carcinoma, Squamous Cell |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
To compare OS in ctDNA(+) patients and ctDNA(-) patients. |
| through study completion, an average of 2 years. |
| Relapse-free survival (RFS) and progression-free survival (PFS). | To compare RFS and PFS in ctDNA(+) patients and ctDNA(-) patients. | through study completion, an average of 2 years. |
| Relationships between radiomics features, ctDNA status and relapse. | To assess if recurrent esophageal cancer is detectable earlier by ctDNA positive in plasma compared to traditional radiographic methods. | through study completion, an average of 2 years. |
| D009369 | Neoplasms |
| D018307 | Neoplasms, Squamous Cell |
| D004938 | Esophageal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D006258 | Head and Neck Neoplasms |
| D004066 | Digestive System Diseases |
| D004935 | Esophageal Diseases |
| D005767 | Gastrointestinal Diseases |